Stay updated on Daratumumab in PGNMID and C3 GN Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in PGNMID and C3 GN Clinical Trial page.

Latest updates to the Daratumumab in PGNMID and C3 GN Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3. No substantive content or layout changes are evident.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedAdded Minnesota as a location under the Locations section and removed the HHS Vulnerability Disclosure text/link from the footer.SummaryDifference0.2%

- Check53 days agoChange DetectedAdded: a note that publications are automatically filled from PubMed and may not be about the study, and a new revision tag (v3.3.2); removed the older PubMed-origin text and the earlier revision tag (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved a general government funding status notice from the page. The notice previously informed users about potential delays and updates due to funding and operating status of NIH facilities.SummaryDifference0.4%

- Check75 days agoChange DetectedThe new version shows minor UI and formatting updates with no changes to the study's core details (eligibility, outcomes, dosing, or locations).SummaryDifference0.4%

- Check103 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

Stay in the know with updates to Daratumumab in PGNMID and C3 GN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in PGNMID and C3 GN Clinical Trial page.